SCHEDULE 13D/A: Major Shareholder Moshe Arkin Boosts Stake in Sol-Gel Technologies to Over 61%

Moshe Arkin and M. Arkin Dermatology Ltd. have significantly increased their beneficial ownership in Sol-Gel Technologies Ltd., now controlling 61.79% of the company's outstanding Ordinary Shares.

Summary

• Moshe Arkin and M. Arkin Dermatology Ltd. filed an Amendment No. 5 to Schedule 13D, updating their beneficial ownership in Sol-Gel Technologies Ltd.
• As of April 28, 2025, Moshe Arkin's total beneficial ownership in Sol-Gel Technologies Ltd. reached 18,449,907 Ordinary Shares, representing approximately 61.79% of the company's outstanding shares.
• M. Arkin Dermatology Ltd. directly owns 18,068,564 Ordinary Shares, accounting for approximately 60.52% of the outstanding shares, with shared voting and dispositive power.
• Moshe Arkin directly owns 381,343 Ordinary Shares, representing approximately 1.37% of the outstanding shares, with sole voting and dispositive power.
• Mr. Arkin is also deemed an indirect beneficial owner of the shares held by Arkin Dermatology due to his role as its sole shareholder and director.
• Recent share purchases by Mr. Arkin include: 33,388 shares at $0.55 on August 21, 2024; 30,000 shares at an average of $0.70 on August 23, 2024; 30,000 shares at an average of $0.61 on August 26, 2024; 46,845 shares at $0.60 on August 27, 2024; 18,995 shares at $0.58 on September 9, 2024; 59,437 shares at $0.66 on April 23, 2025; 50,210 shares at $0.76 on April 24, 2025; 22,823 shares at an average of $0.76 on April 25, 2025; and 3,645 shares at an average of $0.80 on April 28, 2025.
• The beneficial ownership percentages are calculated based on 27,857,620 Ordinary Shares outstanding as of April 15, 2025, as reported by Sol-Gel in its Annual Report on Form 20-F filed on April 29, 2025.

Sentiment

Score: 8

Explanation: The substantial increase in beneficial ownership by a key insider, Moshe Arkin, signals strong confidence in the company's future performance and valuation, which is a highly positive indicator for investors.

Positives

• The significant increase in beneficial ownership by a major insider, Moshe Arkin, indicates strong confidence in the company's future prospects and valuation.
• Moshe Arkin's total beneficial ownership now represents a controlling stake of 61.79%, aligning his interests closely with the long-term success of the company.

Future Outlook

NA

Industry Context

This filing indicates a significant consolidation of ownership by a key insider in Sol-Gel Technologies Ltd., a company operating in the dermatology sector. While not directly addressing broader industry trends, such a substantial increase in insider stake can be interpreted as a strong vote of confidence in the company's specific strategic direction and potential within the competitive dermatology market.

Related Party Transactions

• Moshe Arkin, a significant beneficial owner and sole shareholder/director of M. Arkin Dermatology Ltd., engaged in direct purchases of Sol-Gel Technologies Ltd. Ordinary Shares on multiple dates between August 2024 and April 2025. These transactions are considered related party dealings due to his influential position within the company's ownership structure.

Stakeholder Impact

• Shareholders: The increased insider ownership by Moshe Arkin may instill greater confidence among existing and potential shareholders, as it suggests a strong belief in the company's long-term value by a key stakeholder.
• Management: The significant controlling stake held by Mr. Arkin could lead to more aligned strategic decisions and potentially greater stability in corporate direction.

Key Dates

Recommendation

Keywords

Sol-Gel Technologies, SGLT, Schedule 13D, beneficial ownership, insider buying, Moshe Arkin, M. Arkin Dermatology, SEC filing, Ordinary Shares, corporate control